Previous 10 | Next 10 |
Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds to Neuropilin-2 (NRP2), a unique target expressed on key immune cells in inflamma...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Energous (NASDAQ: WATT ) +143% on FCC certification . More news on: Energous Corporation, Vaxart, Inc., My Size, Inc., Stocks on the move, , Read more ...
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the U.S. Food and Drug Administration (FDA) has accepted its...
aTyr Pharma, Inc. (LIFE) Q4 2019 Earnings Conference Call March 26, 2020 05:00 PM ET Company Participants Jill Broadfoot - Chief Financial Officer and Principal Accounting Officer Sanjay Shukla - President and Chief Executive Officer Conference Call Participants Zegbeh Jallah...
aTyr Pharma (NASDAQ: LIFE ): Q4 GAAP EPS of -$1.54 misses by $0.06 . More news on: aTyr Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO, March 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological path...
Thinly traded nano cap aTyr Pharma (NASDAQ: LIFE ) is up 4% premarket on light volume in reaction to its announcement that Hong Kong subsidiary Pangu BioPharma Limited and the Hong Kong University of Science and Technology have been awarded a $750K grant to build a high-through...
Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies targeting NRP2 SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (...
SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2020 financial r...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...